Hypercholesterolemia Pipeline Therapeutics Market Review H1 2017
PUNE, India, June 2, 2017 /PRNewswire-iReach/ -- RnRMarketResearch.com adds Hypercholesterolemia Pipeline Review H1 2017 to its store. The report provides an overview of the Hypercholesterolemia's therapeutic pipeline with comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects.
Complete report on Hypercholesterolemia Pipeline Review H1 2017 spread across 197 pages is available at http://www.rnrmarketresearch.com/hypercholesterolemia-pipeline-review-h1-2017-market-report.html.
Hypercholesterolemia (Metabolic Disorders) pipeline guide reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 14, 3, 1, 1, 20, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.
Companies discussed in this Hypercholesterolemia Pipeline Review H1 2017 report include 3SBio , AFFiRiS AG, Akcea Therapeutics , Alvogen Korea , ARMO Biosciences , AstraZeneca Plc, BioLingus AG, Catabasis Pharmaceuticals , Chong Kun Dang Pharmaceutical Corp, CymaBay Therapeutics , Daewon Pharm , Daewoong , Dicerna Pharmaceuticals , Dybly AG, Esperion Therapeutics , Gemphire Therapeutics , Golden Biotechnology Corp, Hanmi Pharmaceuticals , Immune Response BioPharma , Johnson & Johnson, Kadmon Corp LLC, Kyorin Pharmaceutical , Leading BioSciences , LipimetiX Development , Lotus Pharmaceutical , Medlab Clinical , Merck , Pfizer , Planet Biotechnology , Progenra , Regeneron Pharmaceuticals , RegenxBio , Serometrix LLC, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical , Solvotrin Therapeutics , The Medicines Company, Viking Therapeutics.
Direct purchase this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=1028944. (This report is available at upto 25% Discount till 02 June 2017).
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities with key players involved in the therapeutics development for Hypercholesterolemia and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects, review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Hypercholesterolemia pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.
Related Report on Hypercholesterolemia Market Available At
Hypercholesterolemia - Market Insights, Epidemiology and Market Forecast-2023.
Hypercholesterolemia - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Hypercholesterolemia forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Hypercholesterolemia till 2023.
Explore more reports on Pharmaceutical Market.
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Media Contact: Ritesh Tiwari, RnRMarketResearch, +1-888-391-5441, sales@rnrmarketresearch.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research
